Thanks for weighing in. Can any non-cell therapy for rrCLL offer a meaningful CR rate at, say, 5 years? We don’t know yet if Breyanzi can do this, but at least it has a chance.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”